Skip to Content
Merck
All Photos(1)

Documents

SML2126

Sigma-Aldrich

NS1209

≥98% (HPLC)

Synonym(s):

(RS)-NS 1209, 2-[[[5-[4-[(Dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid, NS 1209, SPD 502, SPD502

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H28N4O7S
CAS Number:
245063-59-6
Molecular Weight:
516.57
MDL number:
MFCD09955227
UNSPSC Code:
12352200

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CN1CCC(C(C2=CC=C(S(=O)(N(C)C)=O)C=C2)=CC(C3=NOC(CCO)C(O)=O)=C4NC3=O)=C4C1

InChI

1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)

InChI key

CFJRSKULEDUDKL-UHFFFAOYSA-N

Biochem/physiol Actions

NS1209 (SPD 502) is a potent, selective, water-soluble and in vivo long-lasting AMPA antagonist. NS1209 exhibits neuroprotective activity in animal models of stroke, neuropathic pain and epilepsy.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jan M Keppel Hesselink
Drug development research, 78(2), 75-80 (2017-02-15)
Preclinical Research The selective AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist, NS1209 (also known as SPD 502) has been explored in several research and development campaigns since its selection as a lead drug candidate in the early 1990s by the Danish biotechnology
Anne Sabers et al.
Epilepsy research, 106(1-2), 292-295 (2013-04-30)
Refractory status epilepticus (RSE) is a life-threatening condition that requires immediate and aggressive treatment. Unfortunately, sometimes standard antiepileptic treatment is insufficient. Furthermore, alternative therapeutic options are limited by low evidence of efficacy. The primary objective of this study was to
E O Nielsen et al.
The Journal of pharmacology and experimental therapeutics, 289(3), 1492-1501 (1999-05-21)
Accumulating preclinical data suggest that compounds that block the excitatory effect of glutamate on excitatory amino acid receptors may have neuroprotective effects and utility for the treatment of neurodegeneration after brain ischemia. In the present study, the in vitro and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service